1 February 2016
Belleville, Ontario – NovaVive Inc., a Canadian immunobiology company, is pleased to announce that it has United States Department of Agriculture (USDA) and Canadian Food Inspection Agency (CFIA) approval for Immunocidin® to treat equine sarcoid tumors. The Company believes that there is no other regulator-approved equine sarcoid therapy in North America.
Equine sarcoids are locally aggressive fibroblastic neoplasms considered to be the most common skin tumors of horses worldwide. They are often found around the eyes, head/face, neck, chest, and shoulder, and also at the site of old scars. Young to middle-aged horses are most commonly affected by sarcoid tumors.
Current treatment options include surgery, ligation, cryotherapy, topical treatment, chemotherapy, radiation therapy, or laser removal; many of these treatments incur side effects. Immunotherapy is a new, safe and effective treatment option.
Immunocidin is administered by intratumoral injection, but the response is generalized and untreated sites frequently undergo regression as well.
“There are many good reasons to use Immunocidin for equine sarcoids,” said Dr. Stan Alkemade, Chief Veterinary Scientific Officer at NovaVive Inc. “It has a high post-treatment tumor-free rate, is well-tolerated by horses, including older animals, has minimal side effects and an excellent safety profile, and it is an economical treatment option.”
About NovaVive Inc.
NovaVive is a private company founded in July, 2014. The Company has an advanced veterinary immunotherapeutic platform based on mycobacterium cell wall fraction technology with 4 regulator-approved products. Some of these products have demonstrated the capability of reducing the reliance on antibiotics in the treatment of certain diseases of horses and cattle. The Company’s development plan is to identify additional livestock and companion animal diseases that may be effectively treated with its immunotherapeutic technology platform. For more information about Immunocidin or the Company’s other products, visit www.NovaVive.ca.
For further information, contact:
Graeme McRae, President
Graeme.McRae@NovaVive.ca
Phone: 613-391-3837
or
Jennifer Shea, Vice-President, Investor Relations & Business Development
Jennifer.Shea@NovaVive.ca
Phone: 613-391-2097